#Opdivo

FDA Approves Opdivo for Small Cell Lung Cancer

The investigational machine has an 85% accuracy rate.

Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.

Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.

Could new cancer drugs restore immune responses against HIV?

Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.

Study finds that having more diverse gut bacteria was associated with better response to immunotherapy.

Two types of immunotherapy plus chemotherapy shrank tumors in most patients in an early study.

A third of patients taking neoadjuvant Opdivo for inoperable advanced liver cancer had complete responses in an early analysis.

Cabometyx is the third liver cancer drug approved in the past six months.

Treatment with checkpoint inhibitors appears safe and effective for HIV-positive people.

A high-fiber diet may help checkpoint medications work better—but probiotic supplements could interfere with response.

Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.